State Of Alaska, Department Of Revenue I Teos Therapeutics, Inc. Transaction History

State Of Alaska, Department Of Revenue

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 16, 2023	BUY	$10.95 - $14.6 $2,715 - $3,620	248 Added 1.53%	16,485 $180,000
Q2 2023 Jul 24, 2023	SELL	$12.93 - $18.05 $7,395 - $10,324	-572 Reduced 3.4%	16,237 $214,000
Q1 2023 Apr 17, 2023	SELL	$13.02 - $22.62 $3,684 - $6,401	-283 Reduced 1.66%	16,809 $228,000
Q4 2022 Jan 11, 2023	BUY	$17.77 - $21.6 $1,723 - $2,095	97 Added 0.57%	17,092 $333,000
Q3 2022 Oct 20, 2022	BUY	$18.6 - $27.25 $31,155 - $45,643	1,675 Added 10.93%	16,995 $323,000
Q2 2022 Jul 08, 2022	BUY	$16.57 - $35.1 $22,038 - $46,683	1,330 Added 9.51%	15,320 $315,000
Q1 2022 Apr 14, 2022	BUY	$31.92 - $47.45 $446,560 - $663,825	13,990 New	13,990 $450,000

165

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $293M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of State Of Alaska, Department Of Revenue, based on Form 13F filings with the SEC.

Stay updated on State Of Alaska, Department Of Revenue with notifications on news.